Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond

Three New Drugs Reached US Market In 2022

30 Jan 2023

• By Mandy Jackson

Bristol Myers Squibb office building in Brisbane, CA — BMS launched the last three of nine new drugs in 2022 • Source: Shutterstock

Related Content

BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

11 Jan 2022

BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

30 Mar 2021

BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

21 Mar 2022

All Eyes On Bristol's New Launches

26 Oct 2022

BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome

31 Oct 2022

BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

10 Sep 2022

Bristol’s New Products Meet Early Launch Expectations

28 Jul 2022

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

04 Apr 2022

BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use

30 Apr 2022

BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

29 Apr 2022

J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead

10 Jan 2023

Related Companies

Bristol Myers Squibb Company

Amgen, Inc.

Additional Topics

Launches Growth Business Strategies Companies Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.